Diagnostik bullöser Autoimmundermatosen

Lernziele

• Klinische Charakteristika

• Diagnostische Untersuchungen

• Serologische Verlaufsparameter

• Literatur

• 1 Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 1: Clinical manifestations. J Dtsch Dermatol Ges 2011; 9: 844-856
• 2 Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 2: Diagnosis and therapy. J Dtsch Dermatol Ges 2011; 9: 927-947
• 3 Hertl M, Schuler G. [Bullous autoimmune dermatoses. 2: Pathogenesis]. Hautarzt 2002; 53: 277-285
• 4 Sitaru C, Zillikens D. Mechanisms of blister induction by autoantibodies. Exp Dermatol 2005; 14: 861-875
• 5 Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 1991; 67: 869-877
• 6 Nousari HC, Anhalt GJ. Pemphigus and bullous pemphigoid. Lancet 1999; 354: 667-672
• 7 Anhalt GJ. Paraneoplastic pemphigus. J Investig Dermatol Symp Proc 2004; 9: 29-33
• 8 Tsuruta D, Ishii N, Hamada T et al. IgA pemphigus. Clin Dermatol 2012; 29: 437-442
• 9 Schmidt E, Zillikens D. Pemphigoid diseases. Lancet 2013; 381: 320-332
• 10 Gupta R, Woodley DT, Chen M. Epidermolysis bullosa acquisita. Clin Dermatol 2012; 30: 60-69
• 11 Rose C, Brocker EB, Zillikens D. Clinical, histological and immunpathological findings in 32 patients with dermatitis herpetiformis Duhring. J Dtsch Dermatol Ges 2010; 8: 265-270, 265-271
• 12 Terra JB, Pas HH, Hertl M et al. Immunofluorescence serration pattern analysis as a diagnostic criterion in antilaminin-332 mucous membrane pemphigoid: immunopathological findings and clinical experience in 10 Dutch patients. Br J Dermatol 2011; 165: 815-822
• 13 van Beek N, Knuth-Rehr D, Altmeyer P et al. Diagnostics of autoimmune bullous diseases in German dermatology departments. J Dtsch Dermatol Ges 2012; 10: 492-499
• 14 van Beek N, Rentzsch K, Probst C et al. Serological diagnosis of autoimmune bullous skin diseases: prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy. Orphanet J Rare Dis 2012; 7: 49
• 15 Amagai M, Stanley JR. Desmoglein as a target in skin disease and beyond. J Invest Dermatol 2012; 132: 776-784
• 16 Amagai M, Komai A, Hashimoto T et al. Usefulness of enzyme-linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus. Br J Dermatol 1999; 140: 351-357
• 17 Mahoney MG, Wang Z, Rothenberger K et al. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest 1999; 103: 461-468
• 18 Muller R, Heber B, Hashimoto T et al. Autoantibodies against desmocollins in European patients with pemphigus. Clin Exp Dermatol 2009; 34: 898-903
• 19 Hatano Y, Hashimoto T, Fukuda S et al. Atypical pemphigus with exclusively anti-desmocollin 3-specific IgG antibodies. Eur J Dermatol 2012; 22: 560-562
• 20 Rafei D, Muller R, Ishii N et al. IgG autoantibodies against desmocollin 3 in pemphigus sera induce loss of keratinocyte adhesion. Am J Pathol 2011; 178: 718-723
• 21 Frew JW, Murrell DF et al. Paraneoplastic pemphigus (paraneoplastic autoimmune multiorgan syndrome): clinical presentations and pathogenesis. Dermatol Clin 2011; 29: 419-425
• 22 Schepens I, Jaunin F, Begre N et al. The protease inhibitor alpha-2-macroglobulin-like-1 is the p170 antigen recognized by paraneoplastic pemphigus autoantibodies in human. PLoS One 2010; 5: e12250
• 23 Numata S, Teye K, Tsuruta D et al. Anti-alpha-2-macroglobulin-like-1 autoantibodies are detected frequently and may be pathogenic in paraneoplastic pemphigus. J Invest Dermatol 2013; 133: 1785-1793
• 24 Poot M, Diercks GF, Kramer D et al. Laboratory diagnosis of paraneoplastic pemphigus. Br J Dermatol 2013;
• 25 Di Zenzo G, Thoma-Uszynski S, Fontao L et al. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Clin Immunol 2008; 128: 415-426
• 26 Hofmann S, Thoma-Uszynski S, Hunziker T et al. Severity and phenotype of bullous pemphigoid relate to autoantibody profile against the NH2- and COOH-terminal regions of the BP180 ectodomain. J Invest Dermatol 2002; 119: 1065-1073
• 27 Feliciani C, Caldarola G, Kneisel A et al. IgG autoantibody reactivity against bullous pemphigoid (BP) 180 and BP230 in elderly patients with pruritic dermatoses. Br J Dermatol 2009; 161: 306-312
• 28 Lazarova Z, Salato VK, Lanschuetzer CM et al. IgG anti-laminin-332 autoantibodies are present in a subset of patients with mucous membrane, but not bullous, pemphigoid. J Am Acad Dermatol 2008; 58: 951-958
• 29 Bernard P, Antonicelli F, Bedane C et al. Prevalence and clinical significance of anti-laminin 332 autoantibodies detected by a novel enzyme-linked immunosorbent assay in mucous membrane pemphigoid. JAMA Dermatol 2013; 149: 533-540
• 30 Chan LS, Ahmed AR, Anhalt GJ et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol 2002; 138: 370-379
• 31 Woodley DT, Chang C, Saadat P et al. Evidence that anti-type VII collagen antibodies are pathogenic and responsible for the clinical, histological, and immunological features of epidermolysis bullosa acquisita. J Invest Dermatol 2005; 124: 958-964
• 32 Kim JH, Kim YH, Kim S et al. Serum levels of anti-type VII collagen antibodies detected by enzyme-linked immunosorbent assay in patients with epidermolysis bullosa acquisita are correlated with the severity of skin lesions. J Eur Acad Dermatol Venereol 2013; 27: e224-230
• 33 Marzano AV, Cozzani E, Fanoni D et al. Diagnosis and disease severity assessment of epidermolysis bullosa acquisita by ELISA for anti-type VII collagen autoantibodies: an Italian multicentre study. Br J Dermatol 2013; 168: 80-84
• 34 Dainichi T, Kurono S, Ohyama B et al. Anti-laminin gamma-1 pemphigoid. Proc Natl Acad Sci USA 2009; 106: 2800-2805
• 35 Groth S, Recke A, Vafia K et al. Development of a simple enzyme-linked immunosorbent assay for the detection of autoantibodies in anti-p200 pemphigoid. Br J Dermatol 2011; 164: 76-82
• 36 Marinkovich MP, Taylor TB, Keene DR et al. LAD-1, the linear IgA bullous dermatosis autoantigen, is a novel 120-kDa anchoring filament protein synthesized by epidermal cells. J Invest Dermatol 1996; 106: 734-738
• 37 Dieterich W, Laag E, Bruckner-Tuderman L et al. Antibodies to tissue transglutaminase as serologic markers in patients with dermatitis herpetiformis. J Invest Dermatol 1999; 113: 133-136
• 38 Rose C, Dieterich W, Brocker EB et al. Circulating autoantibodies to tissue transglutaminase differentiate patients with dermatitis herpetiformis from those with linear IgA disease. J Am Acad Dermatol 1999; 41: 957-961
• 39 Rose C, Armbruster FP, Ruppert J et al. Autoantibodies against epidermal transglutaminase are a sensitive diagnostic marker in patients with dermatitis herpetiformis on a normal or gluten-free diet. J Am Acad Dermatol 2009; 61: 39-43
• 40 Kasperkiewicz M, Dahnrich C, Probst C et al. Novel assay for detecting celiac disease-associated autoantibodies in dermatitis herpetiformis using deamidated gliadin-analogous fusion peptides. J Am Acad Dermatol 2012; 66: 583-588